-
December 18, 2024 Lupin Receives Approval from U.S. FDA for Emtricitabine and Tenofovir Alafenamide Tablets
-
December 16, 2024 Lupin Digital Health Partners with Medicover Hospitals for Comprehensive Post-Discharge Cardiac Care
-
December 13, 2024 Lupin Acquires 3 Trademarks from Boehringer Ingelheim to Strengthen Diabetes Portfolio
-
December 6, 2024 Lupin Receives Tentative Approval from U.S. FDA for Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension
-
December 5, 2024 Lupin’s R&D Facility in Pune Awarded LEED Platinum Certification
-
November 28, 2024 Lupin Receives Tentative Approval from U.S. FDA for Sitagliptin and Metformin Hydrochloride Tablets
-
November 22, 2024 Lupin’s ESG Score Rises to 76 in S&P Global ESG Ratings
-
November 20, 2024 Lupin and NAPCON Hosts a Walkathon ‘A Step Towards HealThy Lungs’ for COPD Awareness
-
November 19, 2024 Lupin Launches Bumetanide Injection, USP in the United States
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications